Yuko Aoki

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima et al. · Cancer Cell · 2011 · 618 citations · Full text

Molecular Pharmacology, Resistant Gatekeeper Mutant, Drug Discovery +8

Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells

Aikou Okamoto, Takashi Nikaido, Kazunori Ochiai et al. · Clinical Cancer Research · 2005 · 394 citations

Host sphingolipid biosynthesis as a target for hepatitis C virus therapy

Hiroshi Sakamoto, Koichi Okamoto, Masahiro Aoki et al. · Nature Chemical Biology · 2005 · 176 citations · Full text

Biochemistry, Synthetic Virology, Viral Hepatitis +6

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

Nobuya Ishii, Naoki Harada, Eric W. Joseph et al. · Cancer Research · 2013 · 160 citations

Raf Feedback Limits, Raf Activity, Cancer Biology +17

Tetracycline-Regulatable System To Tightly Control Gene Expression in the Pathogenic Fungus <i>Candida albicans</i>

Hironobu Nakayama, Toshiyuki Mio, Shigehisa Nagahashi et al. · Infection and Immunity · 2000 · 152 citations